Tyvaso approval sheet

Jul 31, 2009 · United Therapeutics Corporation Release: FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension - read this article along with other careers information, tips and advice on BioSpace Prescribers should complete the applicable form below and fax it to Humana’s medication intake team (MIT) at 1-888-447-3430. To obtain the status of a request or for general information, you may contact the MIT by calling 1-866-461-7273, Monday – Friday, 8 a.m. – 6 p.m., Eastern time. Jan 17, 2019 · Tyvaso ® (treprostinil) Inhalation Solution. DESCRIPTION. Tyvaso is a sterile formulation of treprostinil intended for administration by oral inhalation using the Tyvaso Inhalation System. Tyvaso is supplied in 2.9 mL low density polyethylene (LDPE) ampules, containing 1.74 mg treprostinil (0.6 mg/mL). Sep 18, 2019 · Tyvaso is intended for oral inhalation using the Tyvaso Inhalation System, which consists of an ultrasonic, pulsed delivery device and its accessories. Tyvaso is dosed in 4 separate, equally spaced treatment sessions per day, during waking hours. Each treatment session will take 2 to 3 minutes.